Overview

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

Status:
Completed
Trial end date:
2008-09-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well SB-715992 works in treating patients with locally advanced, recurrent, or metastatic liver cancer.
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborator:
National Cancer Institute (NCI)